The National Medical Products Administration (NMPA) of China has approved Dizal’s golidocitinib for adults with relapsed or refractory (r/r) peripheral T-cell lymphoma (PTCL). This is the first global approval of a Janus kinase 1 (JAK1) selective inhibitor for r/r PTCL patients whose disease has advanced following a minimum of one previous systemic therapy or who were refractory to this. The gold standard of business intelligence.
PTCL represents a diverse group of aggressive non-Hodgkin lymphomas, with patients at a high risk of disease relapse. The approval is based on the data from the multinational JACKPOT8 Part B study to assess the safety and efficacy of golidocitinib monotherapy in r/r PTCL patients. Objective response rate (ORR) was the trial’s primary endpoint.
Golidocitinib offered superior and lasting antitumor efficacy and had a favourable safety profile versus current treatments. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form The ORR was 44.
3% with a complete response rate of 23.9%, according to an independent review committee. Patients across a range of PTCL subtypes experienced tumour responses, with a median duration.
